Search PubMed⌕ Search

Biomedical subjects

R Lynen

Publications and source records attributed to R Lynen.

27 records · Page 2Linked to original sources
PubMed1983

Characterization of formaldehyde-related antibodies encountered in hemodialysis patients at different stages of immunization.

In hemodialysis patients who reuse formaldehyde-sterilized dialysers we found that antibodies agglutinating native NN red cells belonged exclusively to the IgM fraction of immunoglobulins. In the same patients antibodies directed against formaldehyde-altered NN red cells proved to be mainly IgG in addition to IgM. Three stages of formaldehyde-dependent RBC immunization could be distinguished serologically. The production of these antibodies was dependent on the time of hemodialysis treatment. We found antibodies which could bind complement in the presence of soluble antigen. These antibodies are supposed to damage the patient's red cells immediately after contact to minute amounts of formaldehyde during hemodialysis.

Blood Group Incompatibility↗
PubMed1976

Purification and some properties of factor D of the human properdin system.

Factor D has been purified by gel and ion exchange chromatographies, and by ultrafiltration through different membranes. The final preparation appeared pure in various analytical tests. The molecular weight of human D is 21,500 according to gel chromatography, the isoelectric point was found at pH 7.8. Factor D is an active esterolytic enzyme, it cleaves N-alpha-acetyl-L-lysine methyl ester and N-alpha-acetyl-L-glycyl-L-lysine methyl ester. Both peptide esters inhibit the hydrolytic activation of factor B by D in the presence of cobra venom factor. D is also inhibited by diisopropyl-fluorophosphate and by penylmethyl-sulfonyl-flouride.

Humans↗
PubMed1976

Purification of a human serum protein ("factor E") which enhances cobra venom factor-induced indirect lysis. Identification with the fifth component of complement.

Complexes formed of Cobra venom factor (CVF) and activated factor B (B) by interaction of CVF and B with trypsin or factor D are capable of activating the third and fifth complement component. When incubated with sheep or guinea pig red cells and guinea pig serum in the presence of EDTA, these CVFB complexes produce "indirect lysis". Addition of a human serum factor, earlier designated as factor E (6), greatly enhances the efficiency of this lytic system. The component with this activity has been purified to homogeneity (disc and immunoelectrophoresis). In chromatographic fractionations it was inseparable from the fifth complement component, it was inactivated by and reacted with several anti-C5 antisera, and kinetics of inactivation by heat (56 degrees C) and trypsin were the same for factor E and hemolytic C5 activities. It is concluded that factor E is the fifth component of human complement. Guinea pig C5 is not capable of supporting indirect lysis in a comparable manner, for as yet unknown reasons. Some possible explanations are discussed.

Animals↗
PubMed1975

Formation and composition of the C3 activating enzyme complex of the properdin system. Sequential assembly of its components on solid-phase trypsin-agarose.

An active C3 cleaving enzyme is generated when properdin factor B (glycine-rich beta-glycoprotein, GBG) is activated (GBG is cleaved) by factor D in the presence of C3b and Mg++. Factor D can be replaced by trypsin in this reaction but even then C3b and Mg++ are required. In the absence of C3b and/or Mg++ trypsin does not generate C3 cleaving activity from GBG although it cleaves GBG and releases its GGG fragment (B) under these conditions as well. Addition of C3b to GGG immediately after its release does not yield a C3 cleaving enzyme. These findings indicate that C3b, GBG and Mg++ interact, and that only in association with C3b can GBG be cleaved in a way that its enzyme activity, residing in a C3b, GGG complex, is expressed. The complex is labile (half-life at 20 degrees C: 9 minutes); Mg++ does not affect its stability nor is it essential for the activity. It was possible to sequentially fix on agarose the essential components of the C3 cleaving enzyme and thus to elucidate the single steps and the order of its formation. C3 was activated and the resulting C3b fragment fixed on agarose by incubating C3 with trypsin covalently bound to the agarose. The agarose-C3b intermediate was capable of binding GBG provided Mg++ was present. GBG could then be cleaved by factor D or trypsin added in solution; the solid-phase-fixed complex obtained had C3 cleaving activity, in the presence as well as absence of Mg++. Omission of any of these steps or components, or changes in the sequence did not give rise to an active enzyme. Mixtures of C3b, GBG and Mg++ have weak C3 cleaving activity by themselves. C3 cleavage in such incubation mixtures proceeds slowly for hours and is not accompanied by cleavage of GBG. There is thus complete analogy between the CVF-dependent and C3b-dependent C3 cleaving systems. C3b and CVF act in the same way, they form a reversible, weakly active C3 cleaving complex with GBG and Mg++, the activity of which is markedly enhanced but becomes subject to decay when GBG is cleaved by trypsin-like enzymes while bound to CVF or C3b.

Animals↗
PubMed1975

Cleavage of the third complement component (C3) and generation of the spasmogenic peptide, C3a, in human serum via the properdin pathway: demonstration of inhibitory as well as enhancing effects of epsilon-amino-caproic acid.

Human and guinea pig serum loses hemolytic activity of the third complement component (C3) during incubation at 37 degrees C. The loss is due to specific C3 cleavage involving the properdin system. This is concluded from the finding that C3 inactivation is prevented by EDTA, by elimination of properdin factor B, and unimpaired in C4 deficient guinea pig serum. In the presence of 1 M epsilon-amino-caproic acid (EACA) spontaneous C3 cleavage is considerably enhanced and accompanied by the appearance of biologically active C3a. Lower concentrations of EACA inhibit rather than enhance C3 cleavage in serum. The inhibitory effect of EACA is due to interference with the interaction of the properdin factors and their action on C3 as demonstrated in various systems: the assembly of an active C3-cleaving complex on zymosan, its regeneration after decay by factor D and factor B (GBG), cleavage of GBG by C3b and factor D in systems of purified components, and cleavage of C3 by preformed properdin complexes. Reactions involving the cobra venom factor were likewise depressed. In all these systems EACA was inhibitory even at 1M concentration. No single step in the development or action of an active properdin system was found to be enhanced by 1 M EACA. The enhancing effect of high concentrations of EACA on C3 cleavage in serum may be explained by its observed inhibition of C3b inactivator (C3bINA). This factor controls the properdin system by destroying C3b. In serum the inhibitory effect of 1 M EACA on C3bINA appears to allow escape of the properdin system from its control and thus to increase its net activity toward C3 despite inhibition of the enzymic reactions proper. At lower concentrations the effect of EACA on C3bINA is apparently less significant; therefore, at low concentrations of EACA, its inhibitory effects on C3 cleavage by the properdin system in serum prediominate.

Aminocaproates↗